Down-regulation of miR-9* in the peripheral leukocytes of Huntington’s disease patients

Table 1 Demographic characteristics and blood biochemical parameters of healthy controls and the patients with Huntington’s disease (HD)

	HD (n = 36)	PreHD (n = 8)	Healthy controls (n = 28)
Age (years)	45.58 ± 12.53	29.75 ± 7.21^*	42.03 ± 11.01
Male (%)	20 (55.56)	3 (37.50)	17 (58.62)
HD duration (years)	4.38 ± 3.09
Expanded CAG repeat number	46.42 ± 9.07	44.13 ± 3.17
Drugs (%)
Dopamine antagonist	18 (50.00)	0 (0)	0 (0)
Anti-depressants (SSRI, SNRI, NaSSA)	9 (25.00)	0 (0)	0 (0)
Amantadine	5 (13.89)	0 (0)	0 (0)
UHDRS
Motor score	27.2 ± 18.94	0
Independence scale	78.57 ± 21.98	100
Functional capacity	9.31 ± 3.71	13

Scale ranges (normal to most severe) include motor score (0 to 124), independence scale (100 to 10), and functional capacity (13 to 0)
HD Huntington’s Disease, PreHD pre-sympatomatic Huntington’s disease, NaSSA Noradrenergic and specific serotonergic antidepressant, SNRI Serotonin–norepinephrine reuptake inhibitor, SSRI Selective serotonin re-uptake inhibitors, UHDRS The Unified Huntington’s Disease Rating Scale
^*Statistically significant in comparison with HD patients and healthy controls respectively, P < 0.05, ANOVA with post-hoc Bonferroni test

ISSN: 1750-1172